Drug Profile


Alternative Names: ARQ-197

Latest Information Update: 18 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ArQule
  • Developer ArQule; Daiichi Sankyo Company; Istituto Clinico Humanitas; Istituto Oncologico Veneto; Kyowa Hakko Kirin; National Cancer Institute (USA); National Institutes of Health (USA); SCRI Development Innovations
  • Class Antineoplastics; Pyrrolidinones; Quinolines; Small molecules
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hepatocellular carcinoma
  • Phase II Colorectal cancer; Head and neck cancer; Mesothelioma; Multiple myeloma; Prostate cancer; Renal cell carcinoma; Small cell lung cancer
  • Phase I/II Solid tumours
  • Discontinued Gastric cancer; Germ cell and embryonal neoplasms; Non-small cell lung cancer; Pancreatic cancer; Soft tissue sarcoma

Most Recent Events

  • 02 Jun 2017 Safety and efficacy data from the phase III METIV-HCC trial in Hepatocellular carcinoma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 09 Mar 2017 ArQule has patent protection for tivantinib in US, Japan, the EU, South Korea, Singapore, Australia, China, Mexico, New Zealand, Philippines, Russia and South Africa (ArQule's form 10-K, filed in March 2017)
  • 09 Mar 2017 ArQule has patents pending for tivantinib in USA and countries outside USA (ArQule's form 10-K, filed in March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top